Galmed Pharmaceuticals Ltd. (EOCN) stock
Close on Nov 12, 2026Market cap $2.39MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.19
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.34M
- EPS, diluted
- $19.12
- Book value per share
- $13.38
- Diluted shares
- 1M
Trading
- Previous close
- $2.48
- Open
- $2.39
- Day's range
- $2.27 – $2.51
- Volume
- 3,430
- Average volume (20 days)
- 7,827
- Beta (5 years)
- 1.23
- 52-week range
- $2.05 – $12.32
- RSI (14 days)
- 32.0
- Volatility (1 year)
- 95.4%
- Relative volume
- 0.08×
- WACC
- 11.0%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | EOCN | S&P 500 | Difference | EOCN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.8% | -2.7% | −23.1 pts | ||
| 3 months | -46.7% | -1.7% | −44.9 pts | ||
| Year to date | -60.2% | +11.9% | −72.1 pts | ||
| 1 year | -74.0% | +12.0% | −86.0 pts | ||
| 3 years | -93.4% | +78.2% | −171.6 pts | -59.6% | +21.2% |
| 5 years | -99.9% | +73.2% | −173.2 pts | -77.7% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -53.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Galmed Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Galmed Pharmaceuticals
Pharmaceutical Preparations
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics. Its lead investigational candidate is Aramchol, a compound historically evaluated for the treatment of non-alcoholic steatohepatitis and liver fibrosis. The company is actively working to advance Aramchol into oncological indications outside of liver disorders. In addition, it seeks to broaden and diversify its product development pipeline by targeting innovative candidates for cardiometabolic diseases. Because Galmed remains in the clinical development stage without approved commercial therapies, it operates without conventional commercial end-customer sales and relies primarily on licensing agreements and research collaborations.
Company profile, executives and historyGalmed Pharmaceuticals stock: common questions
What is Galmed Pharmaceuticals's stock price?
EOCN closed at $2.39 on Nov 12, 2026, down 3.63% on the day. Over the past 52 weeks it traded between $2.05 and $12.32.
What is Galmed Pharmaceuticals's market cap?
Galmed Pharmaceuticals was worth $2.39M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does Galmed Pharmaceuticals pay a dividend?
No. Galmed Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has EOCN stock performed over the past year?
Including dividends, EOCN returned -74.0% over the past year, against +12.0% for the S&P 500.
How many EOCN shares are sold short?
0M shares were sold short at the latest FINRA report, 1.02% of the float, or 1.3 days of average trading volume.
Who are Galmed Pharmaceuticals's competitors?
Companies most similar to Galmed Pharmaceuticals by business, industry and size include CANF, XTLB, OCEA, NAMS, CMMB.
See a number that looks wrong?